M&A Deal Summary |
|
|---|---|
| Date | 2004-06-01 |
| Target | Advanced Bionics |
| Sector | Healthcare Services |
| Buyer(s) | Boston Scientific |
| Deal Type | Add-on Acquisition |
| Deal Value | 740M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1979 |
| Sector | Medical Products |
| Employees | 48,000 |
| Revenue | 16.7B USD (2024) |
Boston Scientific is a medical technology company that offers products and technologies used to diagnose and treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. Boston Scientific was founded in 1979 and is based in Marlborough, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 70 |
| Sector: Healthcare Services M&A | 2 of 8 |
| Type: Add-on Acquisition M&A Deals | 8 of 54 |
| State: California M&A | 5 of 29 |
| Country: United States M&A | 7 of 55 |
| Year: 2004 M&A | 1 of 1 |
| Size (of disclosed) | 9 of 36 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2002-07-08 |
BEI Medical System Co.
Teterboro, New Jersey, United States BEI designs, manufactures and markets less-invasive technology used by gynecologists to treat excessive uterine bleeding due to benign causes. BEI's major technology is the Hydro ThermAblator(R) (HTA) System, a less-invasive technology for global endometrial ablation, a procedure designed to eliminate the tissue (the endometrium) responsible for menstrual bleeding. The HTA System allows gynecologists to perform endometrial ablation under direct visualization on an outpatient basis under local anesthesia. More than 200,000 hysterectomies are performed each year in the U.S. for excessive uterine bleeding due to benign causes. |
Buy | $95M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-04-18 |
TriVascular
Santa Rosa, California, United States TriVascular, Inc. is a medical device company that design and manufacture endovascular aortic repair (EVAR). TriVascular’s initial product offerings are novel endovascular grafts focused on significantly advancing EVAR. |
Buy | - |